Taysha Gene Therapies (TSHA) – Analysts’ Weekly Ratings Updates

Taysha Gene Therapies (NASDAQ: TSHA) recently received a number of ratings updates from brokerages and research firms:

  • 11/14/2022 – Taysha Gene Therapies had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $14.00.
  • 11/10/2022 – Taysha Gene Therapies had its price target lowered by analysts at JMP Securities from $22.00 to $20.00. They now have a “market outperform” rating on the stock.
  • 11/10/2022 – Taysha Gene Therapies had its price target lowered by analysts at BTIG Research from $25.00 to $15.00.
  • 11/9/2022 – Taysha Gene Therapies was downgraded by analysts at The Goldman Sachs Group, Inc. from a “buy” rating to a “neutral” rating.
  • 11/9/2022 – Taysha Gene Therapies had its price target lowered by analysts at Chardan Capital from $32.00 to $16.00. They now have a “buy” rating on the stock.
  • 11/8/2022 – Taysha Gene Therapies had its price target lowered by analysts at Needham & Company LLC from $18.00 to $16.00. They now have a “buy” rating on the stock.
  • 11/8/2022 – Taysha Gene Therapies is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $16.00 price target on the stock.
  • 11/8/2022 – Taysha Gene Therapies is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $16.00 price target on the stock.
  • 11/8/2022 – Taysha Gene Therapies had its price target lowered by analysts at Guggenheim from $22.00 to $19.00.
  • 10/26/2022 – Taysha Gene Therapies had its price target lowered by analysts at Robert W. Baird from $26.00 to $21.00. They now have an “outperform” rating on the stock.
  • 10/26/2022 – Taysha Gene Therapies had its price target lowered by analysts at Truist Financial Co. from $35.00 to $15.00.
  • 10/25/2022 – Taysha Gene Therapies had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a “buy” rating on the stock.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $2.22 on Tuesday. The stock has a 50 day moving average price of $2.09 and a 200 day moving average price of $3.07. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 3.40. The company has a market capitalization of $138.62 million, a price-to-earnings ratio of -0.54 and a beta of 1.27. Taysha Gene Therapies, Inc. has a 52-week low of $1.35 and a 52-week high of $15.34.

Insider Buying and Selling at Taysha Gene Therapies

In other news, Director Paul B. Manning acquired 1,500,000 shares of Taysha Gene Therapies stock in a transaction on Monday, October 31st. The stock was bought at an average price of $2.00 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the director now owns 1,642,202 shares in the company, valued at $3,284,404. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 42.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Several large investors have recently modified their holdings of TSHA. Alphabet Inc. purchased a new stake in shares of Taysha Gene Therapies during the third quarter worth approximately $1,237,000. Laurion Capital Management LP purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth approximately $1,646,000. Nantahala Capital Management LLC raised its stake in shares of Taysha Gene Therapies by 23.2% during the second quarter. Nantahala Capital Management LLC now owns 1,643,438 shares of the company’s stock worth $6,114,000 after purchasing an additional 309,491 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Taysha Gene Therapies by 109.0% during the second quarter. Renaissance Technologies LLC now owns 523,600 shares of the company’s stock worth $1,948,000 after purchasing an additional 273,100 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Taysha Gene Therapies during the second quarter worth $804,000. Hedge funds and other institutional investors own 34.28% of the company’s stock.

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Further Reading

Receive News & Ratings for Taysha Gene Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies Inc and related companies with MarketBeat.com's FREE daily email newsletter.